Pfizer’s 25‑valent infant pneumococcal vaccine showed immune responses to all 25 serotypes in Phase 2, company reports
Pfizer's 25‑valent infant pneumococcal vaccine elicited immune responses to all 25 serotypes in Phase 2, with safety similar to Prevnar 20 and stronger serotype 3 responses.